

An Infertile Patient with Abnormal Thyroid-Stimulating Hormone

Shao Feng Mok,^{1*} E. Shyong Tai,¹ Doddabele Srinivasa Deepak,¹ and Tze Ping Loh²

Departments of ¹ Medicine and ² Laboratory Medicine, National University Hospital, Singapore.


* Address correspondence to this author at: National University Hospital, 5 Lower Kent Ridge Rd., Singapore 119074. Fax +65 67771613; e-mail shao_feng_mok@nuhs.edu.sg.

CASE DESCRIPTION

A 35-year-old woman had thyroid function tests performed as part of a workup for infertility. Thyroid-stimulating hormone (TSH) was suppressed at 0.04 mIU/L (reference interval 0.45–4.50) and free thyroxine (fT4) was 1.22 ng/dL [0.77–1.78 ng/dL (15.8 pmol/L, 10–23)]. Results were consistent with subclinical hyperthyroidism.

Five months later, TSH was markedly increased (28.6 mIU/L) while fT4 remained within the reference interval (0.92 ng/dL). Antithyroid peroxidase antibodies (TPOAb) were negative (<40 IU/mL), and TSH receptor autoantibodies (TRAb) were markedly increased at 40 IU/L (<1.8 IU/L). The patient denied any symptoms apart from her infertility.

Based on clinical and laboratory features, the diagnosis of blocking TRAb-related subclinical hypothyroidism (SCH) with infertility was made. The patient was started on thyroxine replacement to reduce TSH to <2.5 mIU/L before in vitro fertilization. She achieved the TSH target 6 month later and conceived successfully after 3 cycles of in vitro fertilization. During pregnancy, her TSH was suppressed, with fT4 within or slightly above the reference interval despite gradual reduction and discontinuation of thyroxine replacement. TSH suppression due to high human chorionic gonadotropin (hCG) concentration in pregnancy usually wanes in the second trimester when hCG concentrations fall. Therefore, this patient's persistent TSH suppression could not be solely accounted for by the effects of hCG (Fig. 1). The patient remained clinically euthyroid throughout the pregnancy. She delivered a healthy boy via a normal vaginal delivery at 39 weeks of gestation. Postpartum, serial monitoring of TSH showed persistent suppression for up to 6 months while the fT4 gradually increased. At this time, her clinical features suggested the development of hyperthyroidism (Fig. 1).



QUESTIONS TO CONSIDER
<ul style="list-style-type: none">• How is SCH defined?
<ul style="list-style-type: none">• What are the subtypes of TRAb and what laboratory assays are used to detect and distinguish between them?
<ul style="list-style-type: none">• What could explain this patient's changes in thyroid hormone testing results and clinical symptoms?

Final Publication and Comments

The final published version with discussion and comments from the experts will appear in the October 2016 issue of *Clinical Chemistry*. To view the case and comments online, go to <http://www.clinchem.org/content/vol62/issue10> and follow the link to the Clinical Case Study and Commentaries.

Educational Centers

If you are associated with an educational center and would like to receive the cases and questions 1 month in advance of publication, please email clinchemed@aacc.org.

All previous Clinical Case Studies can be accessed and downloaded online at <https://www.aacc.org/publications/clinical-chemistry/clinical-case-studies/2016-clinical-case-studies>

AACC is pleased to allow free reproduction and distribution of this Clinical Case Study for personal or classroom discussion use. When photocopying, please make sure the DOI and copyright notice appear on each copy.

AACC is a leading professional society dedicated to improving healthcare through laboratory medicine. Its nearly 10,000 members are clinical laboratory professionals, physicians, research scientists, and others involved in developing tests and directing laboratory operations. AACC brings this community together with programs that advance knowledge, expertise, and innovation. AACC is best known for the respected scientific journal, *Clinical Chemistry*, the award-winning patient-centered web site *Lab Tests Online*, and the world's largest conference on laboratory medicine and technology. Through these and other programs, AACC advances laboratory medicine and the quality of patient care.